Stephen G. Machatha

2022

In 2022, Stephen G. Machatha earned a total compensation of $2.6M as Chief Development Officer at Aldeyra Therapeutics, a 79% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$208,086
Option Awards$818,523
Salary$359,287
Stock Awards$1,167,121
Other$12,200
Total$2,565,216

Machatha received $1.2M in stock awards, accounting for 45% of the total pay in 2022.

Machatha also received $208.1K in non-equity incentive plan, $818.5K in option awards, $359.3K in salary and $12.2K in other compensation.

Rankings

In 2022, Stephen G. Machatha's compensation ranked 1,414th out of 5,753 executives tracked by ExecPay. In other words, Machatha earned more than 75.4% of executives.

ClassificationRankingPercentile
All
1,414
out of 5,753
75th
Division
Manufacturing
705
out of 3,133
78th
Major group
Chemicals And Allied Products
269
out of 1,419
81st
Industry group
Drugs
248
out of 1,320
81st
Industry
Pharmaceutical Preparations
175
out of 966
82nd
Source: SEC filing on May 23, 2023.

Machatha's colleagues

We found two more compensation records of executives who worked with Stephen G. Machatha at Aldeyra Therapeutics in 2022.

2022

Todd Brady

Aldeyra Therapeutics

Chief Executive Officer

2022

Bruce Greenberg

Aldeyra Therapeutics

Chief Financial Officer

News

You may also like